MedPath

Early conversion to cabazitaxel for castration-resistant prostate cancer

Not Applicable
Recruiting
Conditions
castration-resistant prostate cancer
Registration Number
JPRN-UMIN000035375
Lead Sponsor
Sapporo Medical University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1. No previous cabazitaxel treatment 2. Active concomitant malignancy in 3 years except for prostate cancer 3. Difficult to control severe complications except for malignancy 4. Seizure to be treated with anticonvulsant 5. Severe liver dysfunction 6. Allergy for cabazitaxel, docetaxel and predonisolone 7. Neither ability nor will to cooperate the study 8. Unfit for enrollment by physician in charge

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath